UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials

British journal of dermatology (1951), 2024-01, Vol.190 (2), p.289-291

2024

Volltextzugriff (PDF)

Is there still a role for UV therapy in itch treatment?

Experimental dermatology, 2019-12, Vol.28 (12), p.1432-1438

Legat, Franz J.

2019

Volltextzugriff (PDF)

Stable Response and Sustained Improvement of Itch and Sleep Symptoms in Patients with Atopic Dermatitis Treated with Lebrikizumab over 52 Weeks

Dermatology and therapy, 2024-08, Vol.14 (8), p.2171-2180

2024

Volltextzugriff (PDF)

Itch in Hymenoptera Sting Reactions

Frontiers in allergy, 2021-08, Vol.2, p.727776-727776

2021

Volltextzugriff (PDF)

S2k Leitlinie: Diagnostik und Therapie des chronischen Pruritus

Journal der Deutschen Dermatologischen Gesellschaft, 2022-10, Vol.20 (10), p.1386-1402

2022

Volltextzugriff (PDF)

S2k guideline: Diagnosis and treatment of chronic pruritus

Journal der Deutschen Dermatologischen Gesellschaft, 2022-10, Vol.20 (10), p.1387-1402

2022

Volltextzugriff (PDF)

S2k Leitlinie: Diagnostik und Therapie des chronischen Pruritus

Journal der Deutschen Dermatologischen Gesellschaft, 2022-10, Vol.20 (10), p.1386-1402

2022

Volltextzugriff (PDF)

S2k Guidelines for the diagnosis and treatment of chronic pruritus – update – short version

Journal der Deutschen Dermatologischen Gesellschaft, 2017-08, Vol.15 (8), p.860-872

2017

Volltextzugriff (PDF)

S2k‐Leitlinie zur Diagnostik und Therapie des chronischen Pruritus – Update – Kurzversion

Journal der Deutschen Dermatologischen Gesellschaft, 2017-08, Vol.15 (8), p.860-873

2017

Volltextzugriff (PDF)

S2k-Leitlinie zur Diagnostik und Therapie des chronischen Pruritus - Update - Kurzversion

Journal der Deutschen Dermatologischen Gesellschaft, 2017-08, Vol.15 (8), p.860-873

2017

Volltextzugriff (PDF)

311nm ultraviolet B-accelerated response of psoriatic lesions in adalimumab-treated patients

Photodermatology, photoimmunology & photomedicine, 2011-08, Vol.27 (4), p.186-189

2011

Volltextzugriff (PDF)

311 nm ultraviolet B-accelerated response of psoriatic lesions in adalimumab-treated patients

Photodermatology, photoimmunology & photomedicine, 2011-08, Vol.27 (4), p.186-189

2011

Volltextzugriff (PDF)

Human Corneal Epithelial Cells Express Functional PAR-1 and PAR-2

Investigative ophthalmology & visual science, 2003-01, Vol.44 (1), p.99-105

2003

Volltextzugriff (PDF)

The role of calcitonin gene-related peptide in cutaneous immunosuppression induced by repeated subinflammatory ultraviolet irradiation exposure

Experimental dermatology, 2004-04, Vol.13 (4), p.242-250

2004

Volltextzugriff (PDF)

Psoralen plus UVA vs. UVB-311 nm for the treatment of lichen planus

Photodermatology, photoimmunology & photomedicine, 2007-02, Vol.23 (1), p.15-19

2007

Volltextzugriff (PDF)

Retrospective long-term follow-up in patients with chronic palmoplantar dermatoses after good response to bath PUVA therapy

Journal der Deutschen Dermatologischen Gesellschaft, 2012-11, Vol.10 (11), p.814-818

2012

Volltextzugriff (PDF)

Retrospektives Langzeit-Follow-up nach erfolgreicher Bade-PUVA-Therapie bei chronischen palmoplantaren Dermatosen

Journal der Deutschen Dermatologischen Gesellschaft, 2012-11, Vol.10 (11), p.814-819

2012

Volltextzugriff (PDF)

668 - Improvements in itch and sleep disturbance are maintained up to week 48 with nemolizumab plus TCS/TCI treatment in patients with moderate-to-severe atopic dermatitis: results from two global phase 3 pivotal studies (ARCADIA 1 and ARCADIA 2)

British journal of dermatology (1951), 2024-08, Vol.191 (Supplement_2)

2024

Volltextzugriff (PDF)

667 - Maintenance of efficacy and safety with nemolizumab at week 48: results from two global phase 3 pivotal studies (ARCADIA-1 and ARCADIA-2) in patients with moderate-to-severe atopic dermatitis

British journal of dermatology (1951), 2024-08, Vol.191 (Supplement_2)

2024

Volltextzugriff (PDF)

497 - Lebrikizumab in combination with topical corticosteroids maintains improvements in itch and sleep at 68 weeks in patients with moderate-to-severe atopic dermatitis

British journal of dermatology (1951), 2024-02, Vol.190 (Supplement_2), p.ii6-ii7

2024

Volltextzugriff (PDF)

733 - Nemolizumab elicits fast itch response in atopic dermatitis within 2 days: a post hoc analysis of ARCADIA 1 and 2 data

British journal of dermatology (1951), 2024-08, Vol.191 (Supplement_2)

2024

Volltextzugriff (PDF)

436 Nemolizumab monotherapy was associated with significant improvements in prurigo activity score in adult patients with moderate-to-severe prurigo nodularis: results from a phase 3 trial (OLYMPIA 2)

British journal of dermatology (1951), 2023-06, Vol.188 (Supplement_3)

2023

Volltextzugriff (PDF)

Successful thalidomide therapy for actinic prurigo in a European woman

Journal der Deutschen Dermatologischen Gesellschaft, 2006-11, Vol.4 (11), p.961-964

2006

Volltextzugriff (PDF)

Narrowband UV-B vs medium-dose UV-A1 phototherapy in chronic atopic dermatitis

Archives of dermatology (1960), 2003-02, Vol.139 (2), p.223

2003

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Aktive Filter

KollektionIngenta

ThemaMedicine, General & Internal

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(23)

Publikationsform

Sprache

Englisch
(31)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials

Is there still a role for UV therapy in itch treatment?

Stable Response and Sustained Improvement of Itch and Sleep Symptoms in Patients with Atopic Dermatitis Treated with Lebrikizumab over 52 Weeks

Itch in Hymenoptera Sting Reactions

S2k Leitlinie: Diagnostik und Therapie des chronischen Pruritus

Body dysmorphia in common skin diseases: results of an observational, cross‐sectional multicentre study among dermatological outpatients in 17 European countries

S2k guideline: Diagnosis and treatment of chronic pruritus

S2k Leitlinie: Diagnostik und Therapie des chronischen Pruritus

S2k Guidelines for the diagnosis and treatment of chronic pruritus – update – short version

S2k‐Leitlinie zur Diagnostik und Therapie des chronischen Pruritus – Update – Kurzversion

S2k-Leitlinie zur Diagnostik und Therapie des chronischen Pruritus - Update - Kurzversion

311nm ultraviolet B-accelerated response of psoriatic lesions in adalimumab-treated patients

311 nm ultraviolet B-accelerated response of psoriatic lesions in adalimumab-treated patients

Human Corneal Epithelial Cells Express Functional PAR-1 and PAR-2

The role of calcitonin gene-related peptide in cutaneous immunosuppression induced by repeated subinflammatory ultraviolet irradiation exposure

Psoralen plus UVA vs. UVB-311 nm for the treatment of lichen planus

Retrospective long-term follow-up in patients with chronic palmoplantar dermatoses after good response to bath PUVA therapy

Retrospektives Langzeit-Follow-up nach erfolgreicher Bade-PUVA-Therapie bei chronischen palmoplantaren Dermatosen

668 - Improvements in itch and sleep disturbance are maintained up to week 48 with nemolizumab plus TCS/TCI treatment in patients with moderate-to-severe atopic dermatitis: results from two global phase 3 pivotal studies (ARCADIA 1 and ARCADIA 2)

667 - Maintenance of efficacy and safety with nemolizumab at week 48: results from two global phase 3 pivotal studies (ARCADIA-1 and ARCADIA-2) in patients with moderate-to-severe atopic dermatitis

497 - Lebrikizumab in combination with topical corticosteroids maintains improvements in itch and sleep at 68 weeks in patients with moderate-to-severe atopic dermatitis

733 - Nemolizumab elicits fast itch response in atopic dermatitis within 2 days: a post hoc analysis of ARCADIA 1 and 2 data

436 Nemolizumab monotherapy was associated with significant improvements in prurigo activity score in adult patients with moderate-to-severe prurigo nodularis: results from a phase 3 trial (OLYMPIA 2)

Successful thalidomide therapy for actinic prurigo in a European woman

Narrowband UV-B vs medium-dose UV-A1 phototherapy in chronic atopic dermatitis

Aktive Filter

Suchergebnisse filtern